« Return to News | Technology Solutions | Study Conduct

Biogen signs license agreement with PharmaPros

Tuesday, March 22, 2011 11:57 AM

Biogen Idec has signed a three-year enterprise license for PharmaPros' automated study management solution, Dataflow Manager. The deal includes unlimited studies and unlimited users for the duration of the license.

Biogen’s initial implementation of Dataflow Manager consists of four in-progress phase III clinical trials that spanned 36 countries, with more than 5,000 patients and 300 sites, using outsourced service providers for global monitoring and data management. Dataflow Manager provided immediate visibility into the progress of the ongoing studies, delivering real-time analytics on very large data sets including more than 300,000 forms per study, and one million lab records.

PharmaPros is a technology solutions provider specializing in data and workflow management for clinical trials.

"This is an exciting opportunity for PharmaPros, and our product. The initial implementation with Biogen allowed us to test and prove that Dataflow Manager can scale to large, complex clinical trials with very challenging study management criteria, and that both our cloud computing and SaaS delivery model work for clinical trials of any size," said Nick Neri, vice president of technology at PharmaPros.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.